Atara Biotherapeutics Equity 2024

Atara Biotherapeutics Aktienanalyse

What does Atara Biotherapeutics do?

Atara Biotherapeutics Inc. is a biotechnology company founded in 2012 by Isaac Ciechanover. The company is headquartered in South San Francisco, California, and its goal is to develop innovative immunotherapies for the treatment of severe diseases. Atara Biotherapeutics is listed on the NASDAQ stock exchange and has a market capitalization of approximately $1.8 billion. The company's business model focuses on the development of new therapies based on T-cells, the body's own defense cells. T-cells play an important role in fighting diseases like cancer and viral infections. Atara Biotherapeutics is working on leading-edge immunotherapy based on gene-editing to selectively manipulate T-cells to fight certain hard-to-treat diseases. The company has several divisions, including therapy development, clinical research, drug manufacturing, and commercial distribution channels. Its primary focus is on three therapy areas: oncology, virus infections, and autoimmune diseases. Atara Biotherapeutics has partnerships and licensing agreements with leading players in the industry, such as Allergen, Memorial Sloan Kettering Cancer Center, and QIMR Berghofer Medical Research Institute. It has several products in its portfolio, including ATA188 for the treatment of progressive multifocal leukoencephalopathy (PML) and ATA-2271 for mesothelioma. The company also has a pipeline of promising product candidates in various stages of clinical development for cancer, virus infections, and autoimmune diseases. Overall, Atara Biotherapeutics is a leading biotechnology company focused on developing innovative therapies to combat severe diseases. It is well-positioned in the field of immunotherapy with its strong research pipeline, partnerships, licenses, and experienced leadership team. Atara Biotherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Atara Biotherapeutics's Equity

Atara Biotherapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Atara Biotherapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Atara Biotherapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Atara Biotherapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Atara Biotherapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Atara Biotherapeutics stock

What is the equity of Atara Biotherapeutics this year?

Atara Biotherapeutics has equity of -99.23 M USD this year.

What was the equity of Atara Biotherapeutics compared to the previous year?

The equity of Atara Biotherapeutics has increased/decreased by -178.38% decreased compared to the previous year.

What impact does a high equity have on investors of Atara Biotherapeutics?

A high equity is advantageous for investors of Atara Biotherapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Atara Biotherapeutics?

A low equity can be a risk for investors of Atara Biotherapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Atara Biotherapeutics affect the company?

An increase in equity of Atara Biotherapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Atara Biotherapeutics affect the company?

A reduction in equity of Atara Biotherapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Atara Biotherapeutics?

Some factors that can affect the equity of Atara Biotherapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Atara Biotherapeutics so important for investors?

The equity of Atara Biotherapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Atara Biotherapeutics take to change the equity?

To change equity, Atara Biotherapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Atara Biotherapeutics pay?

Over the past 12 months, Atara Biotherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Atara Biotherapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Atara Biotherapeutics?

The current dividend yield of Atara Biotherapeutics is .

When does Atara Biotherapeutics pay dividends?

Atara Biotherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Atara Biotherapeutics?

Atara Biotherapeutics paid dividends every year for the past 0 years.

What is the dividend of Atara Biotherapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Atara Biotherapeutics located?

Atara Biotherapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Atara Biotherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Atara Biotherapeutics from 10/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.

When did Atara Biotherapeutics pay the last dividend?

The last dividend was paid out on 10/5/2024.

What was the dividend of Atara Biotherapeutics in the year 2023?

In the year 2023, Atara Biotherapeutics distributed 0 USD as dividends.

In which currency does Atara Biotherapeutics pay out the dividend?

The dividends of Atara Biotherapeutics are distributed in USD.